CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.
Frequently asked questions
What sector does CORESTEM Inc (166480) operate in?
CORESTEM Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is CORESTEM Inc (166480) current stock price?
As of the latest data, CORESTEM Inc stock price is ₩2,070, with a previous close of ₩2,070.
What is CORESTEM Inc (166480) current market capitalization?
CORESTEM Inc market cap is approximately 99.56 billion.
Does CORESTEM Inc (166480) pay dividends?
No. CORESTEM Inc does not pay a dividend.
What is CORESTEM Inc (166480) beta (volatility) score?
CORESTEM Inc has a beta of 1.582, suggesting it is more volatile than the market.
